Safety and efficacy of repeated sequential administrations of Re-186(Sn)HEDP as palliative therapy for painful skeletal metastases. Initial case reports of two patients.
Single intravenous injections of 30 to 35 mCi (1,110 to 1,295 MBq) of Re-186(Sn)HEDP previously have been shown to result in palliation of painful skeletal metastases from prostate cancer. There are no reports of patients receiving repetitive Re-186(Sn)HEDP therapy. We have followed two such patients who received multiple (five to seven) injections of Re-186(Sn)HEDP at 2-month intervals. Each experienced a sustained decrease in both pain and analgesic intake. The only evident clinical or biochemical toxicity was a mild progressive decline in their total platelet counts.
Eugene L. Saenger Radioisotope Laboratory, University of Cincinnati Medical Center, Ohio 45267-0577.
E E
EE
Englaro
L E
LE
Schroder
S R
SR
Thomas
C C
CC
Williams
H R
HR
Maxon
D000230:Adenocarcinoma / Q000503:physiopathology / Q000556:secondary; D000368:Aged; D001859:Bone Neoplasms / Q000503:physiopathology* / Q000556:secondary; D012968:Etidronic Acid / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009942:Organometallic Compounds / Q000627:therapeutic use*; D010148:Intractable Pain / Q000628:therapy*; D010166:Palliative Care / Q000379:methods*; D010976:Platelet Count; D011471:Prostatic Neoplasms / Q000473:pathology
D009942:Organometallic Compounds; C064573:rhenium-186(tin)etidronate; D012968:Etidronic Acid